UC Davis Spin-off Company, Evolve BioSystems, Secures $20 Million in Funding

UC Davis Spin-off Company, Evolve BioSystems, Secures $20 Million in Funding from Investment Groups to Advance Targeted Microbiome Products

Evolve BioSystems Inc., a spin-off from the UC Davis Foods For Health Institute, that is developing novel solutions to restore and maintain a healthy newborn gut microbiome, announced that it has completed a $20 million Series B financing to fund the commercialization of its initial products.

The company is developing activated probiotic and prebiotic products based on research that shows the infant gut microbiome plays a critical role in the development of a healthy immune system and early metabolic programing as well as meeting the infant’s dietary needs.

Evolve’s founding team, which includes UC Davis faculty members Bruce German, David Mills, Carlito Lebrilla and Daniela Barile, along with previous UC Davis scientist Dr. Samara Freeman, has been conducting research at the forefront of infant nutritional health for over a decade, with a focus on understanding the key role of breast milk in creating a healthy intestinal tract.

The company states the funding will support ongoing clinical activities, operational expansion, and the launch of the initial commercial products. It will also support the development and commercialization of additional animal health products, which aim to restore the balance of nursing animals’ microbiomes.

Read more here.

UC Davis signs agreement to license novel CT scanning technology

UC Davis signs agreement to license novel CT scanning technology

Startup licensee focused on early-stage breast cancer detection and diagnosis

UC Davis has signed a licensing agreement providing Isotropic Imaging Corporation the rights to commercialize a novel computed tomography (CT) scanner that has the potential to improve breast cancer detection and positively impact women’s health.

The technology was developed at UC Davis by a team led by John Boone, professor of radiology and biomedical engineering and a member of the UC Davis Comprehensive Cancer Center. The primary advantage of the scanner is that it provides true three-dimensional and highly-detailed images of the human breast, offering a less obstructed view of potential lesions than provided by current two-dimensional mammograms.

Boone developed the technology as a new tool to diagnose breast cancers in women found to have suspicious lesions following a screening mammogram. Boone said breast CT might replace existing diagnostic breast modalities including mammography, ultrasound and MRI for many patients.

“We know that MRI, used with a contrast agent, is an excellent tool for breast cancer diagnosis, particularly for women at high risk,” Boone said. “And we think that contrast-enhanced breast CT would be equivalent. But it would also be less expensive, quicker and more comfortable for patients.”

Unlike mammography, the scanner does not require compression of the breast. Instead, the patient lies face down on a padded table and places the breast in a circular opening. The scanner generates 300 to 500 images of the breast around 360°, which are then assembled into a three-dimensional digital model. The imaging procedure takes approximately 10 seconds and uses equivalent levels of radiation dose as standard two-view mammography.

With funds from the National Institutes of Health, Boone’s team has assembled four scanners that have been used to image more than 600 women at the UC Davis Medical Center and one other institution as part of a clinical trial.

“Results from a preliminary study show that breast CT scanning was significantly better than mammography for finding masses that could later be identified as cancerous,” Boone said. “In addition, it was found that not only did breast density have much less of a negative impact compared to mammography, participants said that lying down to use the CT scanner was an improvement in comfort versus having their breasts compressed in the mammography machine.”

Boone is currently leading additional clinical trials to compare non-contrast-enhanced CT versus mammography as a breast screening tool for women at average risk of breast cancer.

Robert Thast, CEO of Isotropic Imaging Corp., notes that about one in eight women and one in one thousand men in the United States will be diagnosed with breast cancer during their lifetimes.

“We see a great opportunity to transform how breast cancer is diagnosed with this new approach,” he said.

The license, negotiated by InnovationAccess, within the Technology Management & Corporate Relations division of the UC Davis Office of Research, provides Isotropic Imaging with rights to patents covering novel methods of breast cancer imaging and diagnosis, including a unique algorithm that compensates for imaging differences throughout the breast tissue.

Isotropic Imaging is currently evaluating options to fast track applications with regulatory authorities in the United States and elsewhere. The company is finalizing business and marketing plans in preparation for market launch pending regulatory approvals.

“The interdisciplinary research that led to the development of this exciting technology is emblematic of the One Health and engineering synergies we are realizing at UC Davis,” said Dushyant Pathak, associate vice chancellor for Technology Management & Corporate Relations and executive director of Venture Catalyst at UC Davis. “Our leadership in delivering quality patient care, combined with our strengths in biomedical research and engineering technology development, allow us to enable university-affiliated startups to more effectively translate academic research into societal benefit.”

About Isotropic Imaging Corp.

Isotropic Imaging Corporation is a Nevada-based company established in 2016. It is a wholly owned subsidiary of Canadian-based Izotropic Corporation.

UC Davis to enhance campus innovation and entrepreneurship with $2.2 million from State Innovation & Entrepreneurship Expansion Bill, AB 2664

AB2664

UC Davis-HM.CLAUSE Life Science Innovation Center is one of several business incubators to foster regional innovation.

UC Davis announced today its receipt of $2.2 million in one-time funding from Assembly Bill 2664, the Innovation and Entrepreneurship Expansion bill authored by Assembly member Jacqui Irwin, D-Thousand Oaks, and signed last fall by Governor Jerry Brown. AB 2664 is designed to propel new innovation and entrepreneurship efforts across the University of California through investments in infrastructure, incubators and entrepreneurship education programs. Each of UC’s 10 campuses will receive $2.2 million in one-time funding through this legislative initiative.

“Innovation and entrepreneurship are central to all that we do,” said Ralph Hexter, interim chancellor of UC Davis. “I am excited by this support from the Governor and Legislature that will enable us to launch new programs and expand university infrastructure with the potential to transformatively impact the California economy.”

UC Davis plans to expand its economic engagement activities and collaborations with community stakeholders to enhance the local and regional ecosystem that support innovation and entrepreneurship. With a focus on synergies between the overlapping strengths of the university, region and state, key areas of UC Davis’ AB 2664 program focus include:

  • Expansion of proof-of-concept grant programs to demonstrate commercial feasibility for university technology and boost innovation across a wide range of disciplines
  • Business training and mentorship programs focused on building workforce skills and practical experience in business, entrepreneurship, technology commercialization and startup development
  • Incubator and accelerator programs that provide work and lab space, research and development equipment and instrumentation, and support resources for entrepreneurs.

“AB 2664 funding is important because it allows us to amplify, expand and sustain the success of our uniquely collaborative programs at UC Davis, which enable campus innovators and the entrepreneurial community to interact effectively for regional economic impact,” said Dushyant Pathak, associate vice chancellor for research, and executive director of Venture Catalyst at UC Davis.

“Bolstered by this forward-looking legislative initiative, we can expect to strengthen our partnerships with community stakeholders, enlarge our network of incubator facilities, enhance our entrepreneurial training programs and workshops, and expand resources within the regional innovation and startup ecosystem so as to support broader regional economic development initiatives,” Pathak said.

Managed within the UC Davis Office of Research, program implementation will be driven by the strong collaborative relationship between UC Davis Venture Catalyst and the Mike and Renee Child Institute for Innovation and Entrepreneurship at the UC Davis Graduate School of Management.

The state’s investment will be allocated to support new and expanded activities and programs that will provide direct benefit to campus innovators and entrepreneurs across all disciplines, schools and colleges, as well as to local entrepreneurs whose research can be expected to result in regional economic impact.

Funded programs will be aligned with One Health and Engineering synergies being realized at UC Davis, thereby creating opportunities for innovators and entrepreneurs in disciplines encompassing human health, agriculture, animal health and engineering. Fund allocation will also be extended to existing programs specifically serving the undergraduate community, graduate students and postdoctoral trainees.

Aijun Wang and team

Aijun Wang received the STAIR Grant in 2015. This is one of many programs that will be expanded.

The integration of underrepresented populations in science, technology, engineering and math (STEM) is an important point of emphasis in the delivery of these new and expanded programs. Two notable initiatives are being launched: A novel partnership with UC Merced to create and implement a Central Valley Entrepreneurship Academy focused on regional needs that support the development of an adaptable and innovative workforce in this economically-challenged area; and the development of an annual STEM symposium at UC Davis to showcase successful innovators and entrepreneurs who can serve as instructors, role models, and mentors for women and underrepresented minorities.

“By expanding our innovation and entrepreneurship infrastructure and support programs, UC Davis has the opportunity to effectively translate the almost $800 million of annual research funding it receives into accelerated regional and statewide economic growth through talent development, workforce preparation, technology commercialization and start-up formation,” said Pathak.

Media Resources

Media Contact

UC Davis licenses novel compound that helps stem cells regenerate bone to treat bone diseases

Hybrid molecule LLP2A-Alendronate could have implications for osteonecrosis, fractures, osteoporosis and inflammatory arthritis.

From Left: Fred Tileston (RABOME, Inc.), Ruiwu Liu, Nancy Lane, Christy Pifer, Wei Yao, Kit Lam and Jiwei Chen (RABOME, Inc.)

From Left: Fred Tileston (RABOME, Inc.), Ruiwu Liu, Nancy Lane, Christy Pifer, Wei Yao, Kit Lam and Jiwei Chen (RABOME, Inc.)

The University of California, Davis, is pleased to announce a licensing agreement with Regenerative Arthritis and Bone Medicine, Inc. (RABOME) for a class of drugs developed at UC Davis that hold potential for treating diseases associated with bone loss and inflammatory arthritis.

The license, negotiated by the InnovationAccess team within the UC Davis Office of Research, provides the university affiliated startup with rights to four families of patents and patent applications related to the novel composition of a hybrid molecule, LLP2A-Alendronate, which has been found to effectively direct mesenchymal stem cells (MSCs) to induce bone regeneration in animal models. The compound works by guiding transplanted and endogenous MSCs to the surface of the bone where they differentiate into bone-forming cells, thereby increasing bone mass and strength. These cells are also immune-modulating which help to reduce inflammation at the target sites.

Distal femur from mouse showing more bone marrow (pink) and bone marrow filled with red sinusoids, a sign of higher vascularity, when treated with LLP2A-ALE for 90 days.

Distal femur from mouse showing more bone marrow (pink) and bone marrow filled with red sinusoids, a sign of higher vascularity, when treated with LLP2A-ALE for 90 days.

The use of stem cells as therapeutic agents is a growing field, but directing stem cells to travel and adhere to the surface of bone for bone formation has been an elusive goal in regenerative medicine.

“There are many stem cells, even in elderly people, but they do not readily migrate to bone,” said Wei Yao, co-inventor and associate professor at UC Davis. “Finding a molecule that attaches to stem cells and guides them to the targets we need provides a real breakthrough.”

Translating discovery into societal and commercial impact

Late last year, RABOME received approval from the Food and Drug Administration to begin Phase I clinical trials to evaluate the safety of the drug in humans. The study sites are currently screening patients for enrollment.

“We are pursuing several indications for use, but our initial focus is in developing a treatment for osteonecrosis, a disease caused by reduced blood flow to bones,” said Fred Tileston, president and chief executive officer of RABOME. As many as 20,000 people per year in the United States develop osteonecrosis.

RABOME also plans to pursue other indications for use including fracture healing, osteoporosis and inflammatory arthritis.

“We are pleased that this very promising technology is being shepherded by Mr. Tileston, who is an experienced business leader and entrepreneur,” said Dushyant Pathak, associate vice chancellor for Technology Management & Corporate Relations at UC Davis. “It is exciting to see the team’s progress in translating the discovery into commercial and societal impact.”

Breaking barriers through cross-discipline collaboration

The development of the novel therapy is the result of a successful research collaboration between two teams at UC Davis: a group of experts on bone health, led by Nancy Lane and Wei Yao from the Center for Musculoskeletal Health, and a group of medicinal chemists led by Kit Lam and Ruiwu Liu from the Department of Biochemistry and Molecular Medicine.

“This research was a collaboration of stem cell biologists, biochemists, translational scientists, a bone biologist and clinicians,” said Lane. “It was a truly fruitful team effort with remarkable results.”

Lane and Yao received a Disease Team Therapy Development research grant in 2013 from the California Institute for Regenerative Medicine (CIRM), which along with federal grants from the NIH, supported the preclinical research. CIRM was established in 2004 via California Proposition 71 to fund stem cell research in attempt to accelerate and improve treatments for patients where current needs are unmet.

About RABOME, Inc.

RABOME, Inc., was launched in 2013 to commercialize a class of drugs based on targeting mesenchymal stem cells to various sites of clinical relevance. The company is located in Hillsborough, California.

Media Links

Media Contact

From Ideas to Innovations: Recipients of 2016 STAIR Grants Announced

From ideas to innovation with STAIR grants

August 4, 2016: Venture Catalyst, a unit within the Technology Management and Corporate Relations division of the UC Davis Office of Research, is pleased to announce the recipients of the 2016 Science Translation and Innovative Research, or STAIR, grants.

Now in its third year, the competitive STAIR grant program provides awards of up to $50,000 to help campus entrepreneurs demonstrate proof-of-concept and commercial feasibility of their technologies.

This year’s award recipients are undertaking innovative projects to address a variety of unmet market needs. The 2016 STAIR award winners are:

gino-cortopassiGino Cortopassi, professor, Department of Molecular Biosciences; Alexey Tomilov, assistant project scientist, Department of Molecular Biosciences
Cortopassi and Tomilov have identified several compounds that significantly inhibit Shc, a signaling protein that has been shown to improve the body’s response to insulin and produce resistance to pediatric nonalcoholic fatty liver disease.


richard-levenson

Richard Levenson, professor and vice chair, Department of Pathology and Laboratory Medicine; Farzad Fereidouni, assistant project scientist, Department of Pathology and Laboratory Medicine
Levenson and his team have created an innovative new method for spectral imaging that drastically reduces the amount of data needed for analysis. Their novel approach uses a conventional camera sensor fitted with either a filter wheel or beam-splitting optics.


kai-liu-e1470180402210

Kai Liu, professor, Department of Physics
Liu and his team invented a new method that creates stable skyrmion lattices at room temperature and in zero magnetic field, making them an excellent candidate for energy efficient data storage as well as other nanoelectronics applications.


tony-simon-e1470180329611

Tony Simon, professor, Department of Psychiatry and Behavioral Sciences
Simon has invented a “neurotherapeutic” video game designed to help improve the cognitive abilities of children with genetic disorders such as chromosome 22q11.2 deletion, fragile X, Turner and Williams syndromes, among others.


“The STAIR grant program is unique in many ways,” said Dushyant Pathak, associate vice chancellor for research at UC Davis and executive director of Venture Catalyst. “The structured review process we have developed enables our independent reviewers to effectively assess proposals for technical merit, market need and the ability to effectively achieve commercial milestones. Additionally, this process allows us to provide detailed written feedback to all applicants, which makes the STAIR program part of a continuous improvement and learning process rather than simply a funding opportunity.”

Each STAIR award recipient, as well as all award finalists, are assigned one or more volunteer mentors who review project milestones, offer commercialization guidance, provide business advice, and facilitate networking opportunities and connections to industry. The mentors are selected from the UC Davis Venture Catalyst MentorNet™ program and represent a mix of industry professionals, entrepreneurs and investors. Members of the Venture Catalyst MentorNet also serve on the grant application review committee.

The annual STAIR grant program is open to anyone with principal investigator eligibility at UC Davis. Postdoctoral scholars and staff are eligible to apply as co-principal investigators.

Past STAIR Grant Recipients Make Progress with Innovations

Previous years’ STAIR grant recipients have made significant progress in moving projects forward along the path to commercialization.renal-artery-300x191

Richard Levenson has received a STAIR grant two years in a row. In 2015, he proposed developing a prototype for a new type of microscopy instrumentation. Microscopy with Ultraviolet Surface Excitation, or MUSE, as the novel technology is called, permits the creation of diagnostic-quality images of tissue samples that are generated in minutes using LED light, and eliminates the need for the traditional time-consuming preparation of samples and glass slides.

Levenson credits his STAIR grant as being pivotal in funding the opto-mechanical design of the prototypes that he and his team are assembling which will soon ship to collaborators. “Without STAIR funding, we would not have had the resources to move forward as we have.”

In addition to the creation of the prototypes, two patents have been issued for the invention and a third patent application has been submitted and published. The team has also launched a startup company, MUSE Microscopy Inc.

Related Links

STAIR grant program
2015 Recipients
2014 Recipients
• “Digital neurotherapeutic” game in development at the UC Davis MIND Institute
Magnetic skyrmions at room temperature: New digital memory?

Team develops device that may improve the ability of emergency personnel to properly ventilate pediatric patients

  • News

  1. 1

 

 

 

Team develops device that that may improve the ability of emergency personnel to properly ventilate pediatric patients

Supplying Precious Breath

Dr. Austin Johnson is a physician in the Department of Emergency Medicine and a current scholar in the Mentored Clinical Research Training Program at the UC Davis Clinical and Translational Science Center (CTSC). In 2015, Johnson invented a device that will improve the ability of emergency personnel to properly ventilate pediatric patients (UC Case 2015-841).

Based on a need to deliver the correct volume of air at the required rate, his solution will be particularly helpful with neonatal and pediatric patients, who are much more sensitive to deviations from optimal ventilation rates and volumes than adults.

To help provide optimal ventilator support for pediatric patients, Johnson has developed a device that monitors various parameters, including ventilation rate and tidal volume, and provides audio and/or visual feedback to rescuers. The device is intended to be used by first responders as well as hospital staff. It also integrates with a widely used color coding system that allows rescuers to quickly derive optimal equipment sizes and drug dosages based upon a patient’s height.

In the News
From ideas to innovation STAIR Grant

From Ideas to Innovations: Recipients of 2016 STAIR Grants Announced

Read More

Team develops device that that may improve the ability of emergency personnel to properly ventilate pediatric patients

Read More

Making drugs safer by virtual drug screening

Read More
Follow Us
ConnectContact
FacebookFollow
NewsEmail Newsletter

Making drugs safer by virtual drug screening

Making drugs safer by virtual drug screening

Colleen E. Clancy, Ph.D., is a professor in the Department of Pharmacology at the UC Davis School of Medicine and a pioneer in the field of biophysics.

Together with her team, Clancy studies the mechanisms associated with electrical disorders of the heart. Unlike traditional research methods that rely on animal models or human clinical testing, her laboratory uses complex computational and mathematical predictive modeling approaches to better understand the mechanisms of disease as well as how they are impacted by treatment options.

Cardiotoxicity is one of the most common reasons for drug removal from the market. It often manifests as irregular electrical rhythms with the potential for fatal ventricular arrhythmias, but predicting the beneficial and harmful actions of drugs on the heart’s electrical cycle remains imprecise using current methods.

Clancy and her team have identified a better approach for preclinical drug screening that is both specific and sensitive, and that identifies actual “proarrhythmia,” rather than substitute markers. The approach involves a computational pipeline that starts with drug chemistry profiling and extends all the way to predictions of drug effects in virtual cardiac tissue. By building detailed models of drugs and their interactions with targets at atomic resolution, Clancy’s approach creates the potential to predict these interactions. These computer-generated data are then incorporated into virtual excitable cells, which can be connected to form functional models of tissues. Once established, the model represents a virtual pipeline through which drugs can be screened prior to clinical studies in order to predict unintended cardiac events. It is expected that this versatile technology, upon commercialization, could help to more effectively screen new drugs for efficacy and cardiotoxicity, and also be used to modify drugs that have been removed from the market or failed during clinical testing.

Recently, Clancy’s team developed a model system with the potential to prevent cardiac arrhythmias by predicting drug interactions with a specific potassium ion channel in the heart (UC Case 2016-665). Abnormal drug-induced cardiac electrical activity is most often a side effect from an unintended block of the promiscuous drug target hERG1, the pore-forming domain of the delayed rectifier potassium ion channel in the heart. A block of hERG1 results in prolongation of the QT interval on the ECG, a phase of the cardiac cycle that corresponds to ventricular repolarization.

Not all hERG1 block is proarrhythmic. At present, however, there is no way to distinguish unsafe hERG1 blockers from drugs that are safe. Clancy and her team use their integrative approach, scaling from atom to tissue, to predict the structure-activity relationships that determine proarrhythmia for hERG1- blocking drugs.

Improving Africa’s orphan crops and eradicating stunting in children

Improving Africa’s orphan crops and eradicating stunting in children

UC Davis is partnering with Mars, Inc. in a global plant-breeding consortium that is fighting malnutrition and poverty in Africa by improving the continent’s traditional food crops. These “orphan” crops have been largely ignored by science because they are not internationally traded commodities, but are the food crops grown in the back gardens of the 600 million people who live in rural Africa.

The initiative was inspired by a presentation by Christine Stewart, assistant professor of nutrition at UC Davis, which highlighted the global issue of stunting — a medical affliction resulting from chronic malnutrition that affects a staggering 39% of children in the developing world, and over 130 million children in Africa alone.

The African Orphan Crop Consortium — conceived by Howard Shapiro, a senior fellow in the part-of-th-group-members-counting-cleome-seedsCollege of Agricultural & Environmental Sciences at UC Davis and the chief agricultural officer at Mars — has chartered an ambitious goal to map and make public the genomes of 101 indigenous African food crops. The genomic data gathered on crops will help plant breeders improve the nutritional content, productivity and resilience of Africa’s most important food resources.

The consortium brings together experts from Mars, UC Davis, and a wide range of researchers, industry groups and policymakers. Together, collaborators have contributed about $40 million of in-kind support to the program.

UC Davis has developed an intensive, hands-on curriculum for the consortium’s African Plant Breeding Academy and its state-of-the art genomics laboratory hosted by the World Agroforestry Centre in Nairobi, Kenya. There Africa’s best plant breeding scientists and technicians are being trained to use the latest equipment.

By the end of 2016, more than 50 scientists will have graduated. By July 2016, the group had sequenced 26 whole genomes, resequenced 13, and provided transcriptomes for 21.

“Globally, only 57 plants have ever been genetically sequenced,” Shapiro notes. “The African Orphan Crops Consortium is adding another 101. Graduates of the Academy are professors and heads of research institutes at the top of their game. They now have the ability to make decisions about plant breeding faster, which will lead to higher yielding and more nutritious plants. All of this is happening to benefit some of the poorest people on the planet’s most malnourished continent.”

Through this program, UC Davis faculty travel to Africa and are expected to train 250 breeders over five years. Graduates are already becoming active partners in the orphan crop effort.

women-each-holding-a-measuring-stick-for-their-cleome-plots-prepare-to-sing-after-sowing-seedDaniel Adewale, plant breeder with the Ondo State University of Science and Technology in Okitpupa, Nigeria, graduated last year. He is using the skills he learned to improve the African yam bean, increasing its essential amino acid content and reducing its cooking time. “By helping breeders improve these forgotten crops, I believe the African Orphan Crop Consortium will cure malnutrition in Africa,” Adewale said.

The group collaborates with researchers all over the world, and all of its sequence information will be posted to the internet and offered free to anyone, on the condition it not be patented. “Because we share all our information, we can build on each other’s research,” said Allen Van Deynze, professional researcher with the UC Davis Department of Plant Sciences and a founding member of the consortium, who visits Nairobi each year as part of his commitment to teaching in the academy.

14 new startups based on technologies developed at UC Davis tackle range of scientific, medical, and societal problems

14 new startups based on technologies developed at UC Davis tackle range of scientific, medical, and societal problems

The University of California, Davis, enabled the foundation of 14 commercial startups during the past fiscal year— matching the largest number of new ventures launched in a single year, based on UC Davis technologies.

MUSE Microscopy, one of the startups, is planning to revolutionize the way pathologists identify disease. The company’s technology, jointly developed with Lawrence Livermore National Laboratory, has the potential to save pathologists time and money.

Examining patient tissue under a microscope is critical for research and diagnosing diseases, but preparing samples for slides is costly and time-consuming, taking hours to days. MUSE has developed an alternative: a method that uses short-wavelength ultraviolet light and fluorescent dyes to generate high-definition images of tissue features without the drawbacks of traditional slide preparation.

Logos4n, another startup based on research being conducted at UC Davis, has developed a method to identify individuals’ genomes with high precision, as well as measure genetic changes from development, stress and aging.

Founder and Chief Science Officer Dr. Kiho Cho sees a wide range of possible applications for the company’s genetic surveillance protocols and algorithms such as animal and plant breeding, cell and tissue typing, fundamental cell biology and genetics, and judicial forensics. He also notes several medical applications including genome toxicology (how people’s genomes respond to drugs and environmental toxins), monitoring of radiation therapy, and marker discovery to help diagnose and study diseases.

“Our genetics surveillance technologies have opened the pathway to new understandings of the dynamic genome landscape in biology in general and to individual diagnostics and treatments of some of the most challenging medical conditions in our society,” said Cho.

Several other companies are developing medical applications such as new therapies for high-mortality cancers, Sapience Therapeutics; new anti-inflammatories, AccenGen Therapeutics; a portable non-invasive screening tool for diagnosing traumatic brain injury, Vizzario; and a wearable device for managing vein disorders, VenoSense.

Beyond the biomedical space, UC Davis startups are also tackling important societal problems. Foodful.ly, for example, has created an app to reduce America’s massive food waste problem by alerting users when food is about to go bad and even providing a recipe to uses the item, rather than let it go to waste.

foodfully22

Foodful.ly app notifies user when food is about to expire

Innovation part of University of California culture

University of California campuses, including UC Davis, are powerhouses when it comes to innovation.

In July, the National Academy of Inventors and the Intellectual Property Owners Association ranked University of California number one in the world among universities based on granted U.S. patents. And according to a report by the Bay Area Council Economic Institute, UC researchers and entrepreneurs have spawned hundreds of new companies, contributing more than $20 billion to California’s economy.

This past year UC Davis innovators were issued 35 U.S. and 29 foreign patents. The university also executed 98 copyright licenses, processed 233 records of inventions, filed 200 U.S. and 22 foreign patents, and negotiated 51 licenses and 799 material transfer agreements.

In total, 51 startups, including the 14 new companies for fiscal year 2015-2016, have been formed at UC Davis during the past five years.

Campus entrepreneurs supported by UC Davis Venture Catalyst

Venture Catalyst, within the Technology Management & Corporate Relations division of the UC Davis Office of Research, provides a range of services and resources to help campus inventors and entrepreneurs turn their technologies into companies focused on developing products or services that benefit society.
Venture Catalyst guides researchers through the startup phase including company formation, establishing the appropriate corporate structure, creating connections to mentors and commercial service providers, and provides access to startup incubation facilities.

“This last year, we have seen Venture Catalyst and our collaborative partners support the creation and foundational development of a new cohort of exciting startups based on the novel and compelling research of our faculty, students and staff,” said Dushyant Pathak, associate vice chancellor of research, who also serves as the executive director of Venture Catalyst. “Our startups, with their focus on commercializing effective solutions for pressing societal needs, represent one of the ways in which UC Davis fulfils its mission to serve the greater good of California, the nation and the world.”

Venture Catalyst works closely with campus and local community resources, including its companion units, InnovationAccess and the Office of Corporate Relations, the university’s Child Family Institute for Innovation and Entrepreneurship and local and regional drivers of economic development to support the translation of university research into economic impact.

Venture Catalyst also provides grants to help campus entrepreneurs demonstrate commercial proof-of-concept and the feasibility of their market impact.

UC Davis Startups fiscal year 2015-2016

1. A-Chip. Microfluidic-based diagnostic tool for evaluating inflammatory cell activation and assessing a patient’s risk for a repeat heart attack.
2. AccenGen Therapeutics. Novel anti-inflammatories for indications with the highest unmet needs, such as sinusitis, pain, cardiovascular, respiratory indications and cancer.
3. Amaryllis Nucleics. More efficient RNA-sequencing library synthesis for diagnostics, pharmaceutical development and food security.
4. Biomass Liquefaction Technologies. Innovative process for energy-efficient high solids liquefaction of biomass.
5. Foodful.ly. App that integrates with grocery store purchases to alert users when food is about to go bad and even provides a recipe.
6. GlycoHub. Highly effective enzymatic approaches for high-yield and cost-effective production of complex glycans.
7. Izotropic Corporation. Breast computer tomography for early cancer detection and diagnosis.
8. LOGOS4n. High-resolution genetics, genome, DNA surveillance technologies, to be applied to precision diagnostics and prognostics.
9. MUSE Microscopy, Inc. Novel slide-free microscopy technology for research and diagnostic applications.
10. Protein Architects. Beta solenoid proteins as “molecular Legos” for applications in self-assembly of nanoparticle based devices and materials.
11. Sapience Therapeutics. Novel therapeutics for major unmet medical needs, particularly high-mortality cancers.
12. SensIT. Microelectromechanical-based chemical sensors and information systems.
13.VenoSense. Wearable sensing platform for management of chronic venous disorder.
14. Vizzario. A non-invasive portable screening methodology for diagnosing traumatic brain Injury.

More Information

Media contact:

AJ Cheline, UC Davis Office of Research, 530-752-1101, [email protected]

UC Davis researchers one step closer to creating hand-held device to detect pathogens like E. coli

AstRoNA Biotechnologies is working to create a hand-held device that can be used to detect a variety of pathogens, including foodborne pathogens like E. coli.

AstRoNA Biotechnologies is working to create a hand-held device that can be used to detect a variety of pathogens, including foodborne pathogens like E. coli, pictured here. (Credit: Thinkstock)

Marc Pollack, a Ph.D. student in the UC Davis Microbiology graduate group, and Jeremy Warren, a former postdoc in Plant Pathology, leave Davis at 5 a.m. every weekday morning to commute to IndieBio, a startup accelerator in a narrow alley just south of Market Street in the heart of San Francisco.

It’s where, for four months, they will represent the rest of their team and strenuously refine the business idea behind Astrona, a pathogen detection startup that originated as one of 13 UC Davis interdisciplinary research programs funded by a grant from the Office of Research.

The product they are trying to create is a hand-held device that can be used to detect a variety of pathogens—including foodborne pathogens like E. coli—at all stages in the food supply chain, from fields to restaurants. And the detection technology is applicable to broad range of pathogens, offering potential for other uses such as in the medical field.

The team is now trying to make the leap from a great idea to a viable product. Grappling with the reality that this step may be as difficult, if not more, than the original research, and they are trying to leverage all the resources available to them to increase their chances of success.

Marc Pollack, left, and Jeremy Warren at IndieBio in San Francisco. IndieBio is a startup accelerator in San Francisco. After a four-month program, Pollack and Warren will present AstRoNA Biotechnologies, Inc., to potential investors at IndieBio’s Demo Day this summer.

Marc Pollack, left, and Jeremy Warren at IndieBio in San Francisco. IndieBio is a startup accelerator in San Francisco. After a four-month program, Pollack and Warren will present AstRoNA Biotechnologies, Inc., to potential investors at IndieBio’s Demo Day this summer. (Credit: Astrona)

Accelerators create new ways to launch businesses

Startup accelerators like IndieBio, also known as seed accelerators, are business acceleration programs. Other examples include Y-Combinator and the Illumina Accelerator. The model originated about 10 years ago and has grown in popularity for launching new businesses, particularly in California. The application process is competitive, but if accepted, the accelerator provides seed money and an intensive mentoring and networking program in exchange for a share of the startup’s equity.

Astrona Biotechnologies, Inc., which was founded in 2015 by UC Davis faculty Bryce Falk, Maria Marco, Paul Feldstein, Andre Knoesen, Josh Hihath, Erkin Seker, and Ph.D. students Marc Pollack and Jeremy Warren, is one of 15 companies that are part of IndieBio’s spring 2016 cohort. What unifies the cohorts is they are all using biology as the basis of their technology.

As part of the program, Astrona may receive up to $200,000 in cash and $50,000 in program support from IndieBio in exchange for 8 percent equity in the company. Cohorts accepted into the accelerator move together through a three- to four-month program that involves mentoring and education, culminating in a “Demo Day” where each team presents its now-refined business plan to potential investors, media and the public.

Participating in the accelerator program has been intense for Pollack and Warren, not only because of the long drive and long day (they typically head back to Davis around 7 p.m.), but because of the intense scrutiny given to every aspect of Astrona. Pollack describes a recent mentoring session in which each participant had to examine what purpose they bring to their company. “That kind of intense self-reflection,” which is not something they normally did in the lab, “keeps us focused on why we are here.”

But even more than understanding what role they play within the company, the experience is helping the team refine its product concept. Pollack explains, “It is helping us understand how we fit into the general market. A lot of scientists come up with great ideas and they are great in theoretical mindsets, but when you bring it out into the world it’s important to understand where it fits in for customers.”

Chips for the bioanalyzer in Dr. Marco’s lab. The analyzer uses microfluidics to analyze DNA, RNA, protein, and cells using sample-specific chips.

Chips for the bioanalyzer in Dr. Marco’s lab. The analyzer uses microfluidics to analyze DNA, RNA, protein, and cells using sample-specific chips. (Credit: UC Davis)

A journey with many stepping stones

Astrona’s technology emerged out of a unique interdisciplinary research seed-funding program, Research Investments in Science and Engineering (RISE). In 2012, the university made a bold investment of $10.8 million to fund the RISE program, assembling teams of experts from different disciplines to address global challenges. Astrona arose from one of 13 teams that received funding from the program, bringing together experts in the fields of plant pathology, food science, electrical engineering and computer engineering.

“The accomplishments of the Astrona team exemplifies the effectiveness of interdisciplinary research in finding practical solutions to complex problems,” said Paul Dodd, associate vice chancellor for research. “While the team’s initial work focused on illuminating some of the underpinning biological science, they were able to quickly leverage those insights to develop technology for a potential commercial solution.”

Funding from the RISE program helped to create a rich team-research learning environment where undergraduate students, early-career faculty and more senior academics were able to work together on problems of common interest.

Dr. Maria Marco.

Dr. Maria Marco. (Credit: UC Davis)

Maria Marco, an associate professor in Food Science & Technology, said the RISE program created a unique opportunity for her. “I would have never started working on my own with Erkin and Josh,” who are both assistant professors in Electrical and Computer Engineering. Marco, who studies the microbiome—specifically lactic acid bacteria found in our food and guts—said initially there were challenges simply communicating. “Food science, electrical and computer engineering—we speak a different language. Even among biologists—ecologist and molecular biologists—there are different words and we use different definitions. So part of the challenge was learning to use the words in the right way.”

Marco sees her role as keeping the team grounded regarding pathogen detection, “This is the food environment,” but she remains excited about the technology they have created. “It has real potential to bridge my world with the electrical engineering world.” She laughs when she describes her initial thoughts about how long it would take. “Naively I thought back in 2012 that the engineers had everything worked out and it was just a matter of me telling them ‘Okay, I’m just going to do a little bit of work to get the nucleic acids out of these pathogens and then we can make a device.’”

Actually bridging those two points, though, has been far more arduous. She describes what the team has created as “a process” rather than a product at this point, a specific method to capture and amplify nucleic acid signals for different organisms so the organisms can be detected. For the initial product, the team is focusing on organisms that cause foodborne illnesses, such as the nasty E. coli O157:H7.

As the team progressed, members connected with UC Davis Venture Catalyst seeking assistance in forming a new company based on their vision for the product. Venture Catalyst provides campus entrepreneurs with guidance and resources to help researchers do just that, as well as offering customized services to help them succeed. Astrona participated in Venture Catalyst’s START™ program through which, in addition to company formation, it received help in developing the company’s business plan and assessing its strategy for commercializing its proprietary pathogen detection technology.

“Astrona provides a great example of how campus entrepreneurs can leverage the programs and services offered by the university to translate their cutting-edge research into commercial application,” said Dushyant Pathak, associate vice chancellor of research and executive director of Venture Catalyst. “The early work we do in effectively enabling our campus entrepreneurs, makes our startups more competitive for external resources like those offered by IndieBio.”

To manage their teaching load and their work with the startup, the faculty members are using some of their allowed consulting days to work on Astrona (faculty receive 48 days for an annual appointment, 39 days for nine-month appointment). Pollack is still working on his Ph.D. and is doing his Biotech Internship through the Designated Emphasis in Biotechnology with Astrona. Warren has finished his postdoc in Falk’s lab and is now working for Astrona full-time.

AstRoNA Biotechnologies, Inc., developed out of an interdisciplinary grant from the UC Davis RISE program. From left to right: Bryce Falk, Jeremy Warren, Marc Pollack, Maria Marco, Erkin Seker, Josh Hihath, Andre Knoesen. Not pictured: Paul Feldstein. (UC Davis, May 4th, 2016)

AstRoNA Biotechnologies, Inc., developed out of an interdisciplinary grant from the UC Davis RISE program. From left to right: Bryce Falk, Jeremy Warren, Marc Pollack, Maria Marco, Erkin Seker, Josh Hihath, Andre Knoesen. Not pictured: Paul Feldstein. (Credit: UC Davis, May 4th, 2016)

What’s next? Preparing for “Demo Day”

Back in San Francisco, Pollack and Warren have created a detector (although not quite a product prototype) that they are debugging in time for Demo Day, which will take place this summer. All 15 teams in the spring cohort will participate. The event usually draws about a thousand attendees.

Even though it’s still a few months off, Warren says getting ready for the presentation feels very rushed. “Our science works, but we need to be able to get up there and show how it works. We have seven minutes to wow everybody.”

Links

Contact

Lisa Howard
Communications Specialist
UC Davis Office of Research
[email protected]
(530) 752-8117

Jeremy Warren
CEO, Astrona Biotechnologies
[email protected]
(530) 867 3786